EU agency rejects Sanofi, Isis cholesterol drug
LONDON (Reuters) - European regulators on Friday recommended against approval of Sanofi and Isis Pharmaceutical's drug Kynamro for treatment of a rare genetic disorder that causes unusually high cholesterol.
The European Medicines Agency said it was concerned about the medicine's safety, noting that a high proportion of patients stopped taking it within two years, mainly due to side effects such as flu-like symptoms, injection site reactions and liver toxicity.
The European rebuff contrasts with a green light for the drug, known generically as mipomersen, by a U.S. advisory panel in October.
Sanofi's Genzyme unit said it was disappointed by the decision and planned to request a re-examination.
(Reporting by Ben Hirschler)
- Tweet this
- Share this
- Digg this
- Ukraine says EU to be guarantor in any Russia gas deal
- Rebound in FTSE halted by drop in BT and commodity stocks
- U.S. nurse defies Maine's Ebola quarantine, takes bike ride |
- Shell outpaces peers with profit growth, keeps spending
- Barclays sets aside 500 million pounds for FX fines as profits rise |